Crestwood Advisors Group LLC Invests $294,000 in Exact Sciences Co. (NASDAQ:EXAS)

Crestwood Advisors Group LLC acquired a new stake in Exact Sciences Co. (NASDAQ:EXAS) during the third quarter, according to its most recent filing with the SEC. The firm acquired 4,313 shares of the medical research company’s stock, valued at approximately $294,000.

Other institutional investors also recently bought and sold shares of the company. Vestor Capital LLC acquired a new stake in shares of Exact Sciences in the 3rd quarter worth $46,000. V Square Quantitative Management LLC purchased a new position in Exact Sciences during the third quarter worth about $47,000. Itau Unibanco Holding S.A. acquired a new stake in Exact Sciences in the second quarter valued at about $29,000. EverSource Wealth Advisors LLC boosted its holdings in Exact Sciences by 92.4% in the 1st quarter. EverSource Wealth Advisors LLC now owns 708 shares of the medical research company’s stock valued at $49,000 after purchasing an additional 340 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in Exact Sciences during the 3rd quarter worth approximately $49,000. 88.82% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

EXAS has been the subject of several recent analyst reports. The Goldman Sachs Group reduced their price target on Exact Sciences from $75.00 to $65.00 and set a “buy” rating for the company in a report on Wednesday. Robert W. Baird reduced their target price on Exact Sciences from $70.00 to $67.00 and set an “outperform” rating for the company in a report on Wednesday. Jefferies Financial Group upped their price target on shares of Exact Sciences from $84.00 to $85.00 and gave the stock a “buy” rating in a research note on Wednesday. Stifel Nicolaus cut their price target on shares of Exact Sciences from $82.00 to $67.00 and set a “buy” rating for the company in a report on Wednesday. Finally, Wells Fargo & Company initiated coverage on shares of Exact Sciences in a report on Tuesday, August 27th. They set an “overweight” rating and a $75.00 price objective on the stock. One research analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $75.06.

Insiders Place Their Bets

In other Exact Sciences news, EVP Brian Baranick sold 929 shares of the stock in a transaction on Tuesday, October 8th. The stock was sold at an average price of $70.00, for a total transaction of $65,030.00. Following the transaction, the executive vice president now owns 12,758 shares of the company’s stock, valued at $893,060. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. 1.36% of the stock is owned by corporate insiders.

Exact Sciences Stock Down 23.5 %

EXAS opened at $54.72 on Thursday. The business’s fifty day simple moving average is $67.27 and its 200 day simple moving average is $56.67. Exact Sciences Co. has a 52 week low of $40.62 and a 52 week high of $79.62. The firm has a market cap of $10.11 billion, a P/E ratio of -57.00 and a beta of 1.27. The company has a quick ratio of 1.98, a current ratio of 2.17 and a debt-to-equity ratio of 0.73.

Exact Sciences (NASDAQ:EXAS) last released its quarterly earnings results on Tuesday, November 5th. The medical research company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.01). The firm had revenue of $708.66 million for the quarter, compared to analyst estimates of $716.80 million. Exact Sciences had a negative return on equity of 4.97% and a negative net margin of 6.70%. The firm’s quarterly revenue was up 12.8% on a year-over-year basis. As a group, equities research analysts anticipate that Exact Sciences Co. will post -0.87 EPS for the current fiscal year.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.